Phase 3 Study of Tislelizumab Versus Sorafenib in Participants With Unresectable HCC
Status:
Active, not recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
This is a Phase 3, randomized, open-label, multicenter, global study designed to compare the
efficacy and safety of tislelizumab versus sorafenib as a first-line systemic treatment in
participants with unresectable hepatocellular carcinoma. This study also includes a substudy
investigating the safety, tolerability, PK, and preliminary efficacy in HCC in Japanese
participants. In Japan, preliminary safety and tolerability will be evaluated (Safety Run-In
Substudy) before Japanese participants are recruited in this Phase 3 study.